Hematology & Oncology — Specialty Profile

Exploratory, not prescriptive. This profile blends hard data (pay, match rates, burnout, demographics — each sourced and dated) with generalizations and synthesized online opinion about culture and "who fits." It's here to help you get curious and go find out for yourself — not to tell you who to become. Numbers marked ⟳ verify change every year; check the linked source before you quote one. Last reviewed: 2026-07-25.

Also called: heme/onc, onc, med onc, hematology. Subspecialty fellowship of Internal Medicine, reached through an IM residency and then a fellowship rather than matched out of medical school. Scope: cancer (solid tumors and blood cancers) plus non-cancer blood disorders (clotting, bleeding, anemia, sickle cell). Organ system: blood, bone marrow, lymphatic system, and, through cancer, every organ.

The 30-second version

Hematology & Oncology is the specialty of cancer and blood, the field where medicine's fastest-moving science meets some of its hardest conversations. You diagnose and treat solid tumors and blood cancers, manage non-malignant blood disorders (clots, bleeding, anemias, sickle cell), and walk patients and families through months or years of a life-altering journey: deciding which chemotherapy, targeted agent, or immunotherapy fits this person's tumor biology, running them through treatment in the infusion suite, tracking response, and being present when treatment stops working. It is mostly outpatient, deeply longitudinal, intellectually relentless, and emotionally heavy, and it pays among the top of all Internal Medicine subspecialties.12

Two things make it unusual for a premed to understand up front. First, you get here through Internal Medicine, a residency that is one of the most open doors in US medicine for DO and international graduates, so heme/onc is a high-paying frontier specialty reachable by an accessible route.34 Second, it sits in the middle of a genuine therapeutic revolution: cancers that were uniformly fatal a generation ago are now, for many patients, curable or managed for years like a chronic disease.5

Quick dashboard (details and sources below)
Training after med school IM residency (3) + Heme/Onc fellowship (3) = 6 yrs after med school (combined; heme-only or onc-only = 3 IM + 2)
Total from college start ~14 years (4 undergrad + 4 med school + 3 IM + 3 fellowship)
How you get here Through Internal Medicine — a two-step entry (match IM out of med school, then match the fellowship)
Competitiveness (as an IM fellowship) High — one of the highest-fill IM subspecialties (~99.5% filled, 2026 cycle) ⟳
Typical full-time pay ~$470,000–$535,000 total comp (combined heme/onc) ⟳
Pay range (structure) Community/private practice reaches $600k+; academic $380k–$480k; benign heme lowest ⟳
Lifestyle Mostly outpatient, schedulable — better than acute procedural IM subspecialties; the real cost is emotional, not hours
Burnout High and rising — ~59% of oncologists (ASCO's 2023 MBI survey, n=328). On the cross-specialty instrument, 49.3% against a 41.9% all-physician average (AMA 2025), third of the nine it names ⟳
% women ~36% of practicing oncologists; higher and rising among fellows ⟳
DO / IMG accessibility IMG-heavy (~36% of matched fellows); DO ~8% — accessible mainly via IM ⟳

What they actually do

Hematologist-oncologists manage cancer and blood disorders across a long arc of care. Most US practitioners are dually boarded and practice combined "heme/onc," but the day-to-day splits into recognizable flavors: solid-tumor medical oncology (breast, lung, GI, GU cancers treated with chemo, targeted therapy, and immunotherapy, the bulk of community practice), malignant hematology (leukemias, lymphomas, myeloma, often inpatient-heavy and academic), and benign/classical hematology (clotting, bleeding, anemia, sickle cell, which is cerebral, outpatient, and mostly nothing to do with cancer).67

The core skill is synthesis and judgment: reading a pathology report and molecular/genomic profile, choosing among a firehose of evolving trial-backed regimens, sequencing treatments as disease responds or progresses, managing toxicity, and leading goals-of-care conversations. The work is longitudinal and relationship-dense in a way EM or surgery is not, since you follow the same patients and families for years. It is also one of the most trial-integrated fields in all of medicine; enrolling patients on clinical trials is routine practice, not a research add-on.8

Representative procedures (fewer than most IM procedural subspecialties): bone marrow aspiration and biopsy · lumbar puncture (including intrathecal chemotherapy) · management of infusional chemotherapy/immunotherapy · in BMT/cellular-therapy practice, delivering stem-cell transplant and CAR-T. Most of these are elective and scheduled, not emergent.9

A week in the life (outpatient community model): Mostly clinic: new-consult visits where you deliver a diagnosis and lay out a plan, treatment-decision visits, on-treatment checks for patients in the infusion center, surveillance scans, and survivorship follow-up. You manage the infusion suite in parallel. Inpatient service (consults, admitted patients with neutropenic fever or treatment complications, and in academic centers the leukemia/BMT wards) rotates in blocks rather than being a constant. Call is mostly phone triage; overnight procedural call is limited.10

The training path & time to completion

MD or DO → Internal Medicine residency (3 yrs) → combined Hematology & Oncology fellowship (3 yrs) → dual board eligibility with ABIM in both Hematology and Medical Oncology. You reach this field through IM rather than directly from medical school, which is the single most important structural fact about it.3

  • The combined 3-year fellowship is the dominant path and leads to eligibility for both the Hematology and the Medical Oncology boards (ABIM certifies them as two separate subspecialty certificates). ABIM requires the combined program to include at minimum 18 months of full-time clinical training, of which at least 12 must be in neoplastic disease and 6 in non-neoplastic (benign) hematology.11
  • Single-track alternatives: a 2-year Hematology-only or Medical-Oncology-only fellowship makes you eligible for just one certificate. Less common in the US than the combined route.11
  • Optional advanced year(s): BMT / cellular therapy, or disease-focused training (malignant heme, breast, GU, benign heme, etc.), typically +1 (sometimes +2). Not ACGME-required, but increasingly common for academic and transplant careers.3
  • Board pass rates (2025, first attempt): Hematology 93% on 627 first-time takers, Medical Oncology 90% on 749.11
  • Total time after med school: combined heme/onc = 6 years (3 IM + 3 fellowship). With a BMT/cellular-therapy year, ~7. Heme-only or onc-only = 5 (3 IM + 2). From the start of college, combined ≈ 14 years total.3

The two-step entry note: because this is a fellowship, you have to clear two competitive gates: first match into an IM residency out of medical school, then, during residency, apply and match into a heme/onc fellowship through the NRMP Medicine Subspecialty (Fall) Match. IM board certification is a prerequisite before you can sit for either subspecialty exam.311

How competitive is it? (as an IM fellowship)

Competitiveness here is measured in the NRMP Medicine and Pediatric Specialties Match (the "Fall" fellowship match), not the main residency match. On that scale, heme/onc is one of the most competitive and highest-demand IM subspecialties.12

  • 2026 appointment year (most recent, results released Dec 2025): 809 certified positions offered and 805 filled, a 99.5% fill rate. NRMP/AMA grouped heme/onc among the IM subspecialties offering 150+ positions and filling over 98%, the top tier. It tied gastroenterology for the second-highest fill rate, behind only cardiology.1213 ⟳
  • 2025 appointment year (detailed): 203 programs, 773 positions offered and 771 filled, 99.7%, just under cardiology's 99.8% and at the top of the IM subspecialties alongside it. 1,074 applicants ranked it, for an applicant-to-position ratio ≈ 1.39:1.14 ⟳
  • Who matched (2025, of 771 filled): US MD 55.4% · non-US-citizen IMG 26.8% · US-citizen IMG 9.3% · US DO 8.2% · Canadian 0.3%.14 ⟳
  • Trend: peer-reviewed analyses of NRMP data (2011–2024 and 2014–2025) document rising competitiveness, with applicant growth outpacing modest position growth and pushing fill rates to ~99–100%.15 ⟳

The honest read: the fellowship itself is competitive, but the entry route (IM residency) is one of the most accessible in US medicine, and heme/onc is unusually IMG-friendly for a high-paying field, with over a third of matched fellows IMGs. The bottleneck is real but reachable, especially for a strong IM resident.144

Compensation — the robust version

Heme/onc is a high earner that has risen sharply, and its pay structure is unusually driven by practice model, specifically the economics of administering cancer drugs, rather than by seniority alone. A note on sources first: benchmark surveys disagree because they measure different things (base salary vs. total comp including production and drug-margin distributions) and sample different populations (hospital-employed vs. community private practice). Treat Doximity/AMGA as anchors for headline magnitude, FastRVU's modeled benchmark for the conservative pure-median, and the community-vs-academic split below as the real story.1161718

National number. Depending on source and definition, combined heme/onc lands anywhere from ~$395,000 (FastRVU's modeled pure median) to ~$533,000 (AMGA large-group average). Doximity puts Oncology at $502,465 and Medscape's oncologist figure at $464,000–$472,000 (2024–2025). A defensible "typical full-time" figure for 2025–26 is ~$470,000–$535,000 total compensation, with community/private practice reaching well above.1161718 ⟳

The spread (structure). Crowd data (SalaryDr panel, 121 verified submissions, read 2026-08-17): 25th pct $435,000 · median $495,000 · 75th pct $550,000. Recruiting offers run $310,000 → $700,000 (average starting offer ~$490,000), and FastRVU's illustrative ceilings for integrated practices with infusion + trials reach $568k–$828k. Productivity anchors, from the same FastRVU model: median ~7,200 wRVU/yr at ~$55/wRVU, though some surveys report heme/onc $/wRVU as unusually high, reflecting how much revenue the field generates per unit of clinical work.192021 ⟳

Seniority matters, but practice model matters more. Early-career (0–3 yr) runs ~$400k–$490k; mid-career ~$469k–$520k; senior/partner ~$502k–$588k+, with a late-career premium of roughly +52% over average (Payscale via Physicians Thrive). But the bigger lever is ownership: in private/community practice, "partner" comp far exceeds employed salary because partners share in ancillary/infusion (drug-margin) and clinical-trial revenue.2223 ⟳

The drug-margin ("buy-and-bill") driver is the defining economic feature. This is the thing to understand about oncology pay:

  • Infusion / chemo drug revenue: community practices buy IV chemo and biologics and bill payers at a markup (Medicare Part B pays roughly ASP + 6%, commercial often more). This is a major profit center that flows to physician-owners, and the main reason private-practice comp reaches $600k+. FastRVU estimates infusion-center ownership adds ~$100k–$250k/yr and clinical-trial participation adds ~$50k–$200k+/yr on top of clinical salary.21
  • 340B program (hospitals/large systems): average profit margin on oncology drugs bought through 340B reached ~49% (Berkeley Research Group / Community Oncology Alliance, 2015 data), with 340B hospitals capturing over a third of all Medicare Part B oncology drug reimbursement. This margin has driven hospital acquisition of community practices and shapes employed-model economics.24
  • Large oncology networks (The US Oncology Network/McKesson, OneOncology, American Oncology Network) pool drug-purchasing leverage, ancillaries, and trials, enabling private-practice-level comp with more infrastructure (specific network comp not publicly benchmarked; verify).21

Academic vs. community: the biggest single split. Academic medical centers pay the lowest (~$380k–$480k, trading pay for research, teaching, and salary stability); hospital-employed ~$450k–$520k; community cancer centers ~$460k–$540k; private practice highest at ~$480k–$600k+ because owners share infusion/drug margin and trial revenue.23 ⟳

Sub-field pay differs, too.

  • Solid-tumor medical oncology: comp similar to combined heme/onc (Doximity "Oncology" $502,465), with the heaviest reliance on infusion and drug revenue, so the strongest community upside.1
  • Malignant hematology (leukemia/lymphoma/BMT/CAR-T): concentrated in academic/tertiary centers, so it tends toward the academic pay tier ($380k–$480k) despite high complexity (pattern, not separately benchmarked; verify).6
  • Classical/benign hematology: notably lower. Doximity's standalone "Hematology" line is $421,482 vs. Oncology's $502,465, an ~$80k gap that reflects the absence of oncology drug-margin/infusion revenue. Pure benign heme is the lowest-paid slice.1
  • For contrast (not IM subspecialties): pediatric heme/onc is much lower at ~$250k–$350k; radiation and surgical oncology run separately and higher.23

Geography. Rural/underserved and smaller-metro markets often pay at or above big coastal cities because of shortage-driven demand and less academic competition: recruiter data show upper-Midwest/rural-plains markets at $520k–$600k+, California/New York $500k–$575k, Southeast $450k–$520k. (Crowd "city average" numbers run lower, reflecting cost-of-living and academic mix.) ASCO projects that by 2037 non-metro areas will meet only 29% of oncologist demand vs. 102% in metros, a durable rural recruiting premium.2325 ⟳

Other levers. Locum tenens runs $375–$500/hr (full-time annualizing to ~$700k+); signing bonuses of $50k–$100k are common, plus loan assistance and CME; ~38% of oncologists take on extra work to boost income.212326 ⟳

The trend that colors all of it. Comp is rising, with Hematology +7.4% YoY (Doximity 2024→25) and oncology/hematology +7.1% YoY (AMGA 2023→24), driven by the targeted-therapy and immunotherapy boom (more treatable indications → more drug volume → more infusion revenue) layered on a worsening oncologist shortage. The main downside risk is policy: 340B / Medicare Part B drug-reimbursement pressure and private-equity/hospital consolidation could compress the drug-margin model that underpins high community comp.11727 ⟳

Lifestyle & the emotional-load bargain

The most-cited pro of heme/onc among IM subspecialties: it's a relative lifestyle win. The core work is cognitive and clinic-based, largely schedulable, and light on emergent overnight procedures, considered better than the acute procedural IM subspecialties (cardiology, GI, pulm/critical care). Community/private outpatient oncologists commonly work ~45–55 hrs/week; predictable clinic templates make it comparatively family-compatible.2

The offsetting factor is the whole personality of the field: the real cost is emotional load and volume rather than raw hours or unpredictability. You carry repeated bad-news conversations, end-of-life care, and long relationships that sometimes end in loss. Call is mostly phone triage (neutropenic fever, symptom crises, admissions), heaviest for those doing inpatient malignant heme or transplant; solid-tumor community call is comparatively light. Schedule control is relatively high for physician standards, especially in employed outpatient models, a large driver of the field's appeal.210

Lifestyle rating: 4/5. High schedulability and control for a field this well-paid, with the honest asterisk that the burden here is emotional rather than logistical.

Wellbeing — the part to take seriously

Burnout is high and rising. For cross-specialty scale, the AMA's 2025 Organizational Biopsy puts hematology/oncology at 49.3% against a 41.9% all-physician average, third of the nine specialties it names as most burned out. The field's own instrument reads higher because it measures something different. ASCO's 2023 workforce survey, 328 analyzed responses scored on the Maslach Burnout Inventory's emotional-exhaustion and depersonalization items, put oncologist burnout at 59% against 45% in 2013, and fewer than 25% reported satisfaction with work-life integration (down from ~35% a decade earlier). Among burned-out respondents, roughly three-quarters said they were likely to cut clinical hours within a year and leave their current practice within two, a genuine retention alarm for a field already short-staffed.28 ⟳

The named drivers are two-layered. First, the same system failures hitting all of medicine: EHR and documentation burden, the prior-authorization and insurance friction that gets cited constantly, plus rising volumes and case complexity. Second, and unique to the field, compassion fatigue: a trauma-exposure response (emotional detachment, avoidance, hypervigilance) distinct from system-driven burnout, arising from repeated life-and-death conversations and accompanying patients through end of life. Experts frame it as an occupational near-certainty over a long career rather than a personal failing.29

Satisfaction is a paradox. Despite high burnout, many oncologists report deep meaning and would choose the field again, citing patient relationships and mission. Exhaustion and satisfaction coexist, because the work is draining and profoundly rewarding.30

The upside that keeps people in is intellectual excitement. Heme/onc is widely regarded as the most rapidly advancing field in medicine: targeted therapies, checkpoint-inhibitor immunotherapy, CAR-T and cellular therapies, antibody-drug conjugates, and precision/genomic oncology. Many once-fatal cancers are now chronic or curable, and practitioners frequently cite the pace of progress, and the hope it creates, as a primary source of energy and staying power.5

Career longevity is the real question. Untreated compassion fatigue and grief drive attrition, reduced hours, and early exit, colliding with an existing workforce shortage. The most-cited protective measures are peer-support groups, team debriefs, and normalizing grief as part of the job rather than a weakness.29

Who's in the field (demographics)

  • Women: ~36% of the practicing oncology workforce (2022 ASCO data). Representation among current/incoming fellows is higher and trending toward parity, though no precise fellow-level percentage is quoted here. AAMC's Report on Residents Table B3 and the ACGME Data Resource Book both carry fellow counts by sex.31 ⟳
  • IMG: ~36.2% of matched fellows (2025, US-citizen + non-US-citizen IMGs combined), a notably high share and among the highest of IM subspecialties. Heme/onc is repeatedly cited as one of the IM subspecialties most reliant on IMGs (though the literature also documents bias against IMGs in the recruitment process despite their large presence).4 ⟳
  • DO: ~8.2% of matched fellows (2025). Access for DO graduates runs mainly through the IM route.4 ⟳
  • URiM: oncology remains substantially less diverse than the US population. Among practicing oncologists (2022 ASCO): Black/African American ~3% (vs. 13.6% of the US population), Hispanic/Latinx ~4.7% of oncologists and ~6.2% of oncology fellows (vs. 19.1%), Native American/Alaska Native ~0.1%. These proportions have shown little movement, and ASCO has flagged workforce diversity as a persistent gap.32 ⟳

Culture, personality & the online stereotypes

Who gravitates here: people who want deep, long-term relationships with patients and families over years, not episodic care; intellectually rigorous, evidence- and research-driven minds who enjoy digesting a firehose of new trial data and applying it; physicians comfortable with mortality and serious illness, able to sit with uncertainty and lead hard conversations; and empathetic clinicians who find meaning in accompaniment, not just cure. As always, plenty of people in the field do not fit any single mold.7

The stereotypes. Community caricatures rather than facts, each with an unfair edge:

  • "The saddest specialty; it's all death." Reality: it carries real grief, but this badly undersells the field. Many cancers are now curable or managed as chronic disease for years, and practitioners consistently describe the work as hopeful and uplifting as often as it is heavy: remissions, survivorship, milestones patients never expected to reach.7
  • "Brilliant and kind, but it burns you out emotionally." Half-true: the emotional toll is real, but it's manageable with support, and the "you will inevitably be crushed" framing is overstated. Longevity is common, and the meaning derived is a documented protective factor.7
  • "The most rapidly advancing field in medicine." Stereotype with a strong basis in truth. The therapeutic revolution is genuine, though it also means relentless learning to stay current.7

What people say online (synthesized and paraphrased, not quotes): Across trainee and physician forums the picture is broadly positive and mission-forward, and fellows and attendings frequently describe it as one of the more satisfying IM paths and would pick it again. Lifestyle is discussed as a relative win among IM subspecialties (clinic-based, controllable, light on emergent procedures) with the recurring caveat that emotional labor, not hours, is the true cost. There's a persistent debate over the heme-vs-onc split: benign/classical hematology is described as intellectually elegant and less emotionally punishing, though some worry it's under-reimbursed and being squeezed, while malignant heme and BMT are seen as the most intense and inpatient-heavy. Enthusiasm for the science and pace of change runs high; the loudest complaint is prior-auth and administrative burden as the daily grind that wears people down more than the cancer itself.7

Voices from the field. Paraphrased from public writing, with links to the originals:

  • An oncologist writing for Doximity's Op-Med describes oncology as an intimate field defined by continuity and deep relationships, pushes back on the "depressing" label as inspiring and uplifting work, and points to immunotherapy and personalized medicine as sources of real hope.33
  • Three physicians reporting on compassion fatigue note that essentially anyone practicing heme/onc long enough will feel it, frame it as the brain's protective coping response to repeated distress, and reframe the goal from "how much can you endure" to "how can you thrive and find joy," warning that unaddressed fatigue is a preventable cause of workforce loss.29
  • ASCO's workforce reporting documents burnout climbing to ~59% and the retention risk it poses, tying it to EHR burden, administrative friction, and workload rather than the emotional core of the work alone.28

Why people choose it / why people leave

Why choose it: profound meaning and durable, long-term patient/family relationships · intellectually elite, fast-moving science, since you practice at the research frontier · strong, rising compensation with huge and growing demand · better lifestyle and schedule control than the acute procedural IM subspecialties, and largely outpatient · the real, growing ability to cure or turn once-fatal disease into chronic, livable disease.7

Why leave or avoid it: sustained emotional weight, grief, and compassion-fatigue risk over a career · high and rising burnout, heavily worsened by prior-auth and EHR load · a long training runway (3 IM + 3 fellowship = 6 years post-MD) · the constant obligation to keep up with a relentless flood of new data · end-of-life care is unavoidable and accumulates.7

Best fit if: you want long-term continuity over episodic care · you're energized by rapidly evolving evidence and precision/immuno-oncology · you can hold difficult conversations and sit with mortality without shutting down · you value a controllable, mostly-outpatient schedule · you want a mission-driven career with strong earning power.7

Not for you if: you need emotional distance from patients or find repeated loss unsustainable · you want a procedure- or OR-centric career, or crave acute adrenaline over longitudinal care · you dislike heavy documentation and insurance battles · you want the shortest path to attending life · you prefer problems that are "solved and done" rather than managed over years.7

The FLI angle — Heme/Onc for first-gen, low-income & immigrant students

Where heme/onc fits FLI realities well:

  • A top-of-market income reachable via an IMG/DO-accessible route. This is the headline. The on-ramp is Internal Medicine residency, one of the most accessible US residencies for DO and IMG applicants, and heme/onc itself is unusually IMG-friendly (~36% of matched fellows are IMGs). You don't have to win a hyper-competitive residency straight out of med school; you build toward the field through IM. Few high-paying frontier specialties are this reachable by that route.414
  • Strong, rising pay. Total comp around $470k–$535k (combined), among the higher-earning IM subspecialties, life-changing for someone supporting a family or repaying large loans, and it has been climbing.11726
  • Huge, demographically locked-in demand. New cancer cases in North America are projected to rise +56% (2022→2050) while oncologist density has fallen; ASCO projects deep coverage gaps in rural and community settings for years. That means strong job security and real geographic flexibility, including well-paid roles outside expensive coastal metros, often the best pay-to-lifestyle ratio for a FLI graduate optimizing income and stability.2527
  • Meaningful mission. For students motivated by service and impact, few fields offer a clearer sense of purpose.34

Risks to name honestly:

  • Long runway. ~6 years post-MD (3 IM + 3 fellowship) before attending income, on top of med school, a real cost when you're the breadwinner or carrying debt, and the IM residency/fellowship salary years are modest (fellow stipends ~$70k–$80k). This is the single biggest FLI tradeoff versus, say, going straight into practice after a 3-year residency.322
  • The emotional toll is not free money. The grief and compassion-fatigue burden is genuine and should be entered with eyes open, especially without a strong support network.29
  • The high community pay rests on a policy-sensitive drug-margin model. 340B / Medicare Part B reimbursement changes and private-equity/hospital consolidation are real risks to the buy-and-bill economics that make community heme/onc so lucrative, and they come before any assumption about today’s private-practice numbers are permanent.2427

Bottom line: heme/onc may be the strongest example of a high-paying, high-demand, frontier-science specialty that a first-gen, DO, or IMG student can realistically reach, because the door is Internal Medicine rather than a lottery match out of med school. The price of admission is a long training runway and a permanent emotional load. If the science excites you and the continuity draws you, spend real time in an oncology clinic and an infusion suite, and sit in on a hard conversation, before you commit.

Sub-subspecialties & further training (the flavors within)

Most practitioners do combined heme/onc; the following are the recognized ways to focus deeper, some requiring an extra fellowship year, others just practice emphasis.35

  • BMT / Cellular Therapy (Blood & Marrow Transplant): bone-marrow and stem-cell transplant and CAR-T cellular therapies for blood cancers and marrow failure, the most inpatient-intensive, acute, and high-stakes corner of the field. Usually an added fellowship year, based at academic and tertiary centers.
  • Malignant Hematology: blood cancers, meaning leukemias, lymphomas, myeloma, and myelodysplastic or myeloproliferative disorders. Intellectually demanding, often inpatient-heavy, and at the frontier of new therapies (tends toward the academic pay tier).
  • Benign / Classical Hematology: non-cancer blood disorders: clotting and bleeding disorders, anemias, sickle cell, thrombosis, cytopenias. Cerebral, less emotionally punishing, and more outpatient, though generally the lowest-reimbursed slice.
  • Solid-Tumor Medical Oncology: solid cancers (breast, lung, GI, GU, etc.) treated with chemo, targeted therapy, and immunotherapy. The bulk of community oncology, mostly outpatient and infusion-based, and the strongest community-comp upside.
  • Disease-Specific Oncology: focused expertise in a single cancer type (breast, lung/thoracic, GI, GU, melanoma, neuro-oncology, sarcoma), common in academic and large-group settings where deep specialization and trial work concentrate.

Fun facts

  • It's a two-for-one board: US fellows typically certify in both Medical Oncology and Hematology, spanning cancer care and non-malignant blood disorders.36
  • CAR-T cell therapy, which engineers a patient's own immune cells to attack cancer, went from experimental to standard of care in a striking span, and heme/onc is where it's delivered.36
  • Some "cancers" are now managed like chronic diseases: CML, once rapidly fatal, is often controlled for decades with a daily oral pill (tyrosine kinase inhibitors).36
  • Classical and benign hematology (clotting, bleeding, anemias) has almost nothing to do with cancer, and a sizable slice of the field never treats a tumor.36
  • Oncology is one of the most trial-integrated specialties in all of medicine, where enrolling patients on clinical trials is routine practice rather than a research add-on.36
  • It is consistently ranked among the fastest-advancing fields in medicine, with FDA cancer-drug approvals arriving at a pace few other specialties see.36

Sources

Training & competitiveness

Compensation

Demographics

Lifestyle, wellbeing, culture & FLI

Footnotes

  1. Doximity 2025 Physician Compensation Report (2024 data) — Oncology $502,465 avg (#17), Hematology $421,482 avg (#22), Hematology +7.4% YoY; the ~$80k onc-vs-heme gap. https://www.doximity.com/reports/physician-compensation-report/2025. 2025. Corrected 2026-08-17: Hematology was given as #21. Counted down the report's Compensation by Specialty table from Neurosurgery, Pulmonology ($425,700) sits at 21 and Hematology at 22. Both dollar figures are exact. ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7

  2. Lifestyle — hours (~45–55 hrs/week community outpatient), outpatient clinic + infusion setting, limited overnight procedural call, high schedule control; better than acute procedural IM subspecialties. Heme/onc lifestyle research compilation, mid-2026 (synthesizing sources below); Medscape Physician Lifestyle Reports 2024 (https://www.medscape.com/sites/public/lifestyle/2024). ↩ ↩2 ↩3

  3. Training path, years, combined vs. single-track fellowships, optional advanced years, total time after med school. Compiled from NRMP Medicine Subspecialties Match data and ABIM/ACGME training requirements. NRMP SMS Results & Data 2025 (https://www.nrmp.org/wp-content/uploads/2025/02/SMS_Results_and_Data_2025.pdf); ACGME Data Resource Book AY2024–2025 (https://www.acgme.org/globalassets/pfassets/publicationsbooks/2024-2025_acgme_databook_document.pdf). 2026. ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  4. Fellowship-pipeline IMG (~36.2%) and DO (~8.2%) shares (2025 matched cohort), and heme/onc's high IMG reliance. NRMP SMS Results & Data 2025 (https://www.nrmp.org/wp-content/uploads/2025/02/SMS_Results_and_Data_2025.pdf); JCO Oncology Practice, "Bias Against IMGs…" (2022, https://ascopubs.org/doi/10.1200/OP.22.00219) and "Call for… Recruitment of IMGs" (2024, https://ascopubs.org/doi/10.1200/OP.24.00022). 2025. ↩ ↩2 ↩3 ↩4 ↩5

  5. Intellectual excitement / therapeutic revolution — targeted therapy, immunotherapy, CAR-T/cellular therapy, ADCs, precision oncology; many cancers now chronic or curable. Heme/onc research compilation, mid-2026. ↩ ↩2

  6. Field overview — combined heme/onc as the dominant dually-boarded model, with solid-tumor onc, malignant heme, and classical/benign heme flavors; malignant-heme pay pattern toward the academic tier (pattern, verify — not separately benchmarked). Heme/Onc compensation research compilation, mid-2026 (synthesizing sources below). ↩ ↩2

  7. Culture, who-gravitates, stereotypes, synthesized online sentiment (r/oncology, r/hematology, r/Residency, SDN — paraphrased, not quoted), and decision-guide (why choose/leave, best-fit/not-for-you). Heme/onc lifestyle & culture research compilation, mid-2026. ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10

  8. Trial-integration as routine practice; combined-boarding scope. Heme/onc research compilation, mid-2026. ↩

  9. Representative procedures (bone marrow biopsy, LP/intrathecal chemo, infusional therapy management; BMT/CAR-T in cellular-therapy practice), mostly elective/scheduled. Heme/onc research compilation, mid-2026. ↩

  10. Week-in-the-life (outpatient community model), call structure (phone triage; heaviest for inpatient malignant heme/transplant), and block inpatient service. Heme/onc research compilation, mid-2026. ↩ ↩2

  11. ABIM dual certification (Hematology and Medical Oncology as separate subspecialty certificates), combined-program training minimums, 2-year single-track eligibility, and 2025 first-attempt pass rates. Pass rates, from ABIM's own table: Internal Medicine and Subspecialty Certification Examinations: 2021-2025 First-Time Taker Pass Rates gives Hematology 531/90%, 522/94%, 592/92%, 562/94%, 627/93% across 2021 to 2025, and Medical Oncology 630/91%, 678/92%, 702/92%, 720/90%, 749/90% — so the 2025 columns are Hematology 93% on 627 takers and Medical Oncology 90% on 749, https://www.abim.org/certification/pass-rates/. Training minimums: "a minimum of 18 months of full-time clinical training", of which "at least 12 of these months must be in the diagnosis and management of a broad spectrum of neoplastic diseases" and "6 months in the diagnosis and management of a broad spectrum of non-neoplastic hematological disorders." BoardVitals, "How Do I Become Dual Certified in Hematology and Oncology?" summarizing ABIM policy (https://www.boardvitals.com/blog/hematology-oncology-dual-certification/); ABIM subspecialty policies (https://www.abim.org/certification/policies/internal-medicine-subspecialty-policies/hematology/). 2025. Corrected 2026-08-17: two errors, both from reading the secondary rather than ABIM's own tables. The pass rates were transposed — this page had Hematology 90% and Medical Oncology 93%, which is the order BoardVitals prints and the reverse of ABIM's. And the 18 months was read as the oncology figure with the 6 benign-hematology months added on top, which inflated the oncology minimum by half and turned an 18-month requirement into a 24-month one; the 18 is the total and it contains the 6. ↩ ↩2 ↩3 ↩4

  12. 2026 appointment-year Match — 809 positions offered, 805 filled, 99.5% fill; heme/onc among IM subspecialties filling >98%. NRMP, "NRMP Celebrates Results for the 2025 Medicine and Pediatric Specialties Match" (Dec 2025) (https://www.nrmp.org/about/news/2025/12/nrmp-celebrates-results-for-the-2025-medicine-and-pediatric-specialties-match/). 2025. ↩ ↩2

  13. Highest-fill IM subspecialties, 2026 cycle (cardiology 100%, GI 99.5%, heme/onc 99.5%, rheumatology 99%, pulm/CC 98.8%). AMA, "Dig into NRMP fellowship Match data for medicine, pediatrics" (https://www.ama-assn.org/medical-residents/medical-fellowships/dig-nrmp-fellowship-match-data-medicine-pediatrics). 2025. ↩

  14. 2025 appointment-year detailed data — 203 programs, 773 offered, 771 filled (99.7%), 1,074 applicants (~1.39:1), and matched-fellow breakdown by applicant type (US MD 55.4%, non-US IMG 26.8%, US IMG 9.3%, DO 8.2%, Canadian 0.3%). NRMP SMS Results & Data 2025 (https://www.nrmp.org/wp-content/uploads/2025/02/SMS_Results_and_Data_2025.pdf). 2025. Corrected 2026-08-17: the bullet called 99.7% the highest fill rate of any IM subspecialty that cycle. Table 1A of the cited report puts Cardiovascular Disease above it, at 1,260 filled of 1,262 offered, 99.8%, so heme/onc was not first. The bullet directly above already had the ordering right for 2026 — "behind only cardiology" — and cardiology led in 2025 too, so the two bullets now tell one story. Everything else in the bullet is exact against the table. A one-program "Oncology" listing in the same block filled 2 of 2 for a nominal 100%, which is why the sentence names cardiology rather than claiming a rank. ↩ ↩2 ↩3 ↩4

  15. Rising-competitiveness trend from peer-reviewed NRMP analyses (specific ratios not individually extractable — verify). ASH Blood, "Tracking fellowship competitiveness in hematology-oncology (2014–2025)" (2025) (https://ashpublications.org/blood/article/146/Supplement%201/8213/552366/); "Unveiling the Competition… (2011–2024)" (2024) (https://ashpublications.org/blood/article/144/Supplement%201/7947/526650/). 2024–2025. ↩

  16. Medscape Oncologist Compensation Report — $472,000 (2024, pub. 2025) and $464,000 (2025, pub. 2026, down ~2%; ranked 9th of 29; 52-hr avg week; 75% received an incentive bonus). Via mdlinx.com (https://www.mdlinx.com/article/oncologists-are-among-medicine-s-highest-earners-but-the-full-picture-is-complicated/38TlEKoU5GG8ZI9Al3UxP7) and beckersoncology.com (https://www.beckersoncology.com/oncology/oncologist-compensation-falls-2-what-to-know/). 2025–2026. ↩ ↩2

  17. AMGA (American Medical Group Association) — oncology/hematology $533,402 (2024, pub. July 2025), +7.1% from $498,062 in 2023; large group-practice dataset. Via Becker's Hospital Review (https://www.beckershospitalreview.com/oncology/oncology-hematology-compensation-up-7-1-since-2023.html). 2025. ↩ ↩2 ↩3 ↩4

  18. FastRVU's modeled benchmark — $395,000 median, range $330k–$520k (the conservative pure-median anchor on this page). https://fastrvu.com/specialties/hematology-oncology. 2026. Corrected 2026-08-17: this footnote and two body sentences credited the $395,000 median to MGMA. FastRVU's page says it is not a licensed MGMA table, so the label was false, and it is gone from all three. FastRVU is named where a reader meets the number, because an aggregator figure stays where it is the only figure there is. The number itself is unchanged. ↩ ↩2

  19. SalaryDr (crowd-sourced, 121 verified submissions, read 2026-08-17) — 25th pct $435,000, median $495,000, 75th pct $550,000; heme/onc $531,458 average. https://www.salarydr.com/specialty/hematology-oncology. 2026. Corrected 2026-08-17: this footnote gave 119 submissions and a $530,726 average against a body sentence that said 121, two readings of one continuously-growing panel sitting in one file. The panel's page now reads 121 and $531,458; the three percentiles were unchanged by the drift. ↩

  20. AMN / Merritt Hawkins, 2025 Review of Physician Recruiting Incentives — recruiting-offer range $310,000→$700,000, average starting offer ~$490,000. https://www.amnhealthcare.com/blog/physician/perm/hematology-oncology-salary-trends-for-2025/. 2025. ↩

  21. FastRVU — wRVU productivity (median 7,200/yr, ~$55/wRVU), infusion-center ownership (+$100k–$250k/yr), clinical-trial participation (+$50k–$200k+/yr), integrated-practice earnings ceiling ($568k–$828k), and large-network structure. https://fastrvu.com/specialties/hematology-oncology. 2026. (Higher $/wRVU corroborated by Marit Health 2025, https://www.marithealth.com/posts/2025-wrvus-by-specialty-and-per-wrvu.) On Marit Health: it publishes a panel of self-reported physician salaries, and displays MGMA and AMGA benchmarks beside them that are masked unless you create an account. The figure quoted here comes from the self-reported panel, not from either benchmark. Read it as crowd data: unweighted, of unstated sample size, and directional. Corrected 2026-08-17: the wRVU line in the spread paragraph carried an "(MGMA 2026)" label that belonged to this FastRVU model, and the integrated-practice ceiling ran unattributed. Both now name FastRVU in the visible sentence. The infusion-ownership and clinical-trial bullets already named it. ↩ ↩2 ↩3 ↩4

  22. Career-stage comp (early $400k–$490k, mid $469k–$520k, senior/partner $502k–$588k+), late-career +52% premium, and fellow stipend (~$70k–$80k, verify). All Star Healthcare 2026 (https://allstarhealthcaresolutions.com/blog/hematologist-oncologist-salary-guide/); Physicians Thrive 2024 (https://physiciansthrive.com/physician-compensation/hematologist). 2024–2026. ↩ ↩2

  23. Practice-setting ranges (academic $380k–$480k, hospital-employed $450k–$520k, community cancer center $460k–$540k, private practice $480k–$600k+); regional ranges; pediatric heme/onc contrast ($250k–$350k); the ownership/revenue-share mechanism. All Star Healthcare 2026 (https://allstarhealthcaresolutions.com/blog/hematologist-oncologist-salary-guide/); corroborated by MDLinx (https://www.mdlinx.com/article/oncologists-are-among-medicine-s-highest-earners-but-the-full-picture-is-complicated/38TlEKoU5GG8ZI9Al3UxP7). 2026. ↩ ↩2 ↩3 ↩4 ↩5

  24. 340B oncology-drug economics — ~49% average profit margin (Berkeley Research Group / Community Oncology Alliance, 2015 data), 340B hospitals capturing >1/3 of Medicare Part B oncology drug reimbursement, driving hospital acquisition of community practices. AJMC (https://www.ajmc.com/view/average-profit-margin-on-oncology-drugs-for-340b-hospitals-nears-50). Consolidation context: Drug Channels (https://www.drugchannels.net/2023/10/the-battle-for-oncology-margin-how.html). ↩ ↩2

  25. Geographic pay pattern and rural premium; ASCO 2025 workforce projections (non-metro meeting only 29% of demand by 2037 vs. 102% metro; 4% of oncologists in high-cancer-mortality counties). All Star Healthcare 2026 (https://allstarhealthcaresolutions.com/blog/hematologist-oncologist-salary-guide/); ASCO (https://www.asco.org/about-asco/press-center/news-releases/new-ASCO-report-explores-US-oncology-workforce). 2025–2026. ↩ ↩2

  26. Locum tenens ($375–$500/hr, ~$700k+ FTE), signing bonuses ($50k–$100k), and moonlighting (~38% of oncologists). Barton Associates 2026 (https://www.bartonassociates.com/oncologist-hematologist-salary-guide/); All Star Healthcare 2026 (https://allstarhealthcaresolutions.com/blog/hematologist-oncologist-salary-guide/); Weatherby (https://weatherbyhealthcare.com/blog/medical-oncologist-salary). 2024–2026. ↩ ↩2

  27. Compensation trend (Hematology +7.4% Doximity 2024→25; oncology/hematology +7.1% AMGA 2023→24), targeted-therapy/immunotherapy tailwind, demand surge (+56% new cancer cases 2022→2050 vs. falling oncologist density; ASCO), and consolidation/reimbursement downside risk. Doximity 2025; AMGA 2024; ASCO (https://www.asco.org/about-asco/press-center/news-releases/new-ASCO-report-explores-US-oncology-workforce); AJMC/Drug Channels (as above). 2025–2026. ↩ ↩2 ↩3

  28. Oncologist burnout 59% (2023, against 45% in 2013); <25% satisfied with work-life integration; ~75% of burned-out respondents likely to cut hours/leave. Primary: Schenkel C, et al., "State of Professional Well-Being, Satisfaction, and Career Plans Among US Oncologists in 2023," JCO Oncology Advances (2025), https://pmc.ncbi.nlm.nih.gov/articles/PMC11789616/ — "In all, 328 responses to the 2023 survey were analyzed," scored on "two single-item measures of emotional exhaustion (EE) and depersonalization (DP) from the Maslach Burnout Inventory (MBI) Human Services Survey for Medical Personnel," and "45% in 2013 versus 59% in 2023 (P < .01)." Relayed by Oncology News Central (2024, https://www.oncologynewscentral.com/oncology/most-oncologists-are-dissatisfied-and-burned-out-asco-report-shows). Corrected 2026-08-17: the page carried the 59% with neither the instrument nor the sample size, so a reader had no way to tell it apart from the cross-specialty screeners other profiles on the Sky quote. Both are now in the visible sentence and the primary is cited. The AMA's 2025 Organizational Biopsy publishes a hematology/oncology row at 49.3% against a 41.9% all-physician baseline; it is a different instrument on a different baseline and the two must not be read against each other. ↩ ↩2

  29. Compassion fatigue as a distinct trauma-exposure response, its near-inevitability over a career, and protective measures; burnout drivers (EHR, prior-auth). Lee A, Ackerman M, Bickel J, via Medscape / The Hospitalist (2025, https://blogs.the-hospitalist.org/content/compassion-fatigue-how-oncologists-can-recognize-signs). ↩ ↩2 ↩3 ↩4

  30. Satisfaction paradox — high burnout coexisting with deep meaning and high would-choose-again. Heme/onc research compilation, mid-2026; Medscape, "'Why Did I Choose This?' Tackling Burnout in Oncology" (https://www.medscape.com/viewarticle/997683). ↩

  31. Women ~36% of the practicing oncology workforce (2022 ASCO data); higher and rising among fellows (precise fellow-level % not confirmed — verify against AAMC Report on Residents Table B3 / ACGME Data Resource Book). ASCO Post (2024, https://ascopost.com/issues/november-10-2024/ensuring-an-inclusive-environment-for-female-minority-oncologists/); AAMC Table B3 (https://www.aamc.org/data-reports/students-residents/data/report-residents/2024/table-b3-number-active-residents-type-medical-school-gme-specialty-and-gender). 2022/2024. ↩

  32. URiM representation among practicing oncologists (2022 ASCO) — Black ~3%, Hispanic/Latinx ~4.7% (oncologists) / ~6.2% (fellows), Native American/Alaska Native ~0.1% — vs. US population shares. ASCO Post (2023, https://ascopost.com/issues/november-10-2023/how-asco-is-tackling-the-need-to-improve-workforce-diversity-and-the-looming-oncology-workforce-shortage). 2023. ↩

  33. Shikha Jain, MD — oncology as an intimate, continuity-driven field; pushback on the "depressing" label; immunotherapy/personalized medicine as hope. Doximity Op-Med (https://opmed.doximity.com/articles/why-oncology-is-an-intimate-field-d0cf0ce3-287a-46c7-8158-b2776ae4c65c). ↩

  34. FLI angle — mission/meaning, and demand-driven job security/geographic flexibility. Barton Associates 2026 (https://www.bartonassociates.com/oncologist-hematologist-salary-guide/); heme/onc research compilation, mid-2026. ↩

  35. Sub-subspecialties (BMT/cellular therapy, malignant heme, benign/classical heme, solid-tumor onc, disease-specific onc). Heme/onc research compilation, mid-2026; Medical College of Wisconsin heme malignancies/BMT overview (https://www.mcw.edu/departments/medicine/divisions/hematology-oncology-cancer/research/hematologic-malignancies-blood-and-marrow-transplant-bmt-cellular-therapy). ↩

  36. Fun facts (dual boarding, CAR-T, CML-as-chronic-disease, benign heme, trial integration, pace of FDA approvals). Heme/onc research compilation, mid-2026. ↩ ↩2 ↩3 ↩4 ↩5 ↩6

Researched with AI assistance and reviewed by hand. How this site is made